Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer® biologics and pre|CISION™ tumour targeted chemotherapies.
| Industry: | Health Care |
| Sector: | Health Care |
| Website: | avacta.com |
| Twitter: | @avacta |
| Exchange: | LSE |
| Admission date: | 26 Jan 2016 |
| Market: | Aim |
| Region: | Europe |
No Results & Reports data for this company
| 28 Sep 2023 | Investor Presentation via Investor Meet Company |
| 28 Jun 2023 | Annual General Meeting |
| 28 Jun 2023 | Annual General Meeting and Shareholder Event |
| 25 Apr 2023 | Investor Webinar |
| 16 Apr 2023 | Annual Meeting |
| 23 Jun 2022 | Annual General Meeting |